中国骨质疏松杂志

双膦酸盐联合降糖药对2型糖尿病合并骨质疏松症大鼠BMP-2、TGF-β1、IGF-1的影响

Effects of bisphosphonate combined with hypoglycemic agents on BMP-2, TGF-β1 and IGF-1 in type 2 diabetic mellitus with osteoporosis rats

DOI：10.3969/j.issn.1006-7108.2020.10.002

中文关键词: 2型糖尿病合并骨质疏松症阿仑膦酸钠二甲双胍胰岛素样生长因子-1 转化生长因子-β1 骨形态发生蛋白-2

英文关键词:type 2 diabetes with osteoporosis alendronate metformin insulin-like growth factor-1 transforming growth factor-β bone morphogenetic protein-2

基金项目:

作者	单位
孙杨1 高玮2* 杨素琴3	1.首都经济贸易大学体育部，北京丰台 100070 2.首都经济贸易大学校医院，北京丰台 100070 3.北京市丰台区新村社区卫生服务中心全科，北京丰台 100070

摘要点击次数: 487

全文下载次数: 357

中文摘要:

目的观察研究双膦酸盐联合降糖药对2型糖尿病合并骨质疏松症大鼠BMP-2、TGF-β1和IGF-1表达的影响，以探讨其防治DOP的作用机制。方法 60只雌性SD大鼠随机分为对照组、模型组、双膦酸盐组、降糖药组、联合组，构建2型糖尿病合并骨质疏松症大鼠动物模型并给予不同药物干预。分别检测糖代谢、骨密度和骨生物力学指标；RT-PCR和免疫组化分别检测骨组织BMP-2、TGF-β1、IGF-1mRNA和蛋白表达。结果双膦酸盐组、降糖药组、联合组血清FPG、2hBPG、HbAlc较模型组均显著降低（P<0.05）；双膦酸盐组、降糖药组、联合组血清FINS较模型组显著升高（P<0.05）。双膦酸盐组、降糖药组、联合组骨组织BMC和骨生物力学指标较模型组均显著升高（P<0.05）。双膦酸盐组、降糖药组、联合组骨组织BMP-2、TGF-β1、IGF-1mRNA和蛋白表达较模型组均显著升高（P<0.05）。结论双膦酸盐联合降糖药可能通过调控2型糖尿病合并骨质疏松大鼠BMP-2、TGF-β1、IGF-1表达，以改善糖代谢，增加骨密度和提高骨生物力学性能，发挥防治DOP作用。

英文摘要:

Objective To observe the effect of bisphosphonate combined with hypoglycemic agents on the expression of BMP-2, TGF-β1 and IGF-1 in type 2 diabetic with osteoporosis rats, and to explore its mechanism of prevention and treatment of DOP. Methods 60 female SD rats were randomly divided into control group, model group, bisphosphonate group, hypoglycemic agent group, combined group, An animal model of type 2 diabetes mellitus complicated with osteoporosis was established and given different drug interventions. Glucose metabolism, bone mineral density and bone biomechanics were detected respectively, RT-PCR and immunohistochemistry were used to detect the expression of IGF-1, IRS-1 and IRS-2 mRNA and protein in bone tissue. Results The serum levels of FPG, 2hBPG and HbAlc in the bisphosphonate group, hypoglycemic group and combination group were significantly lower than the model group (P<0.05), The serum levels of FINS in the bisphosphonate group, hypoglycemic group, and combination group were significantly higher than the model group (P<0.05). The BMC and bone biomechanical index in the bisphosphonate group, hypoglycemic group, combined group were significantly higher than the model group (P<0.05). The mRNA and protein expression profiles of the bisphosphonate group, hypoglycemic group and combination group were significantly higher than the model group (P<0.05). Conclusion Bisphosphonate combined with hypoglycemic agents may regulate the expression of BMP-2, TGF-β1 and IGF-1 in type 2 diabetes mellitus with osteoporosis rats, improve glucose metabolism, increase bone density and improve bone biomechanical properties, and play a role in prevention and treatment of DOP effect.

查看全文查看/发表评论下载PDF阅读器

关闭